



# Investor Presentation

January 26, 2022

Nasdaq: ATRA

Ola  
EBV+ PTLD Advocate



# Forward-Looking Statements

---

This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, future transactions, business strategy, product candidates, correspondence with regulatory authorities, regulatory submissions, regulatory approvals, the initiation, timing, progress and results of preclinical studies and clinical trials and our research and development programs, ability to sell, manufacture or otherwise commercialize our product candidates, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, our ability to obtain and maintain intellectual property protection for our product candidates, and the sufficiency of Atara's cash, cash equivalents, short-term investments to fund its planned operations are forward-looking statements of Atara Biotherapeutics, Inc. ("Atara" or the "Company"). These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "predict," "plan," "expect" or the negative or plural of these words or similar expressions. These forward-looking statements are subject to risks and uncertainties, including those discussed in Atara's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. These risks and uncertainties include, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the certainty and timing of closing our asset sale related to the Atara T-Cell Operations and Manufacturing facility, the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the impact of future and pending legislation and regulations; the use of our information technology and communication systems and cybersecurity attacks; the sufficiency of our cash resources and need for additional capital, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Atara's own internal estimates and research. While Atara believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Atara's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

The content of this presentation is subject to copyright, which will be asserted by Atara and no part of this presentation may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without prior permission in writing from Atara.

# Atara Biotherapeutics Enters Strategic Manufacturing Partnership with FUJIFILM Diosynth Biotechnologies (FDB)



## Partnership Includes Long-term Supply Agreement, for Clinical and Commercial Product Manufacturing and Other Related Services Resulting in Reduced Operating Expenses for Atara



- FDB to acquire Atara's cell therapy manufacturing facility (ATOM) for \$100M at closing, with plans to retain all manufacturing and quality staff at the site
- Recognizes the industry leading position of Atara's manufacturing staff and capabilities in allogeneic cell therapy
- FDB is a world-leading contract development and manufacturing organization with experience in the development and manufacture of biologics, vaccines and advanced therapies
- The parties have also entered into a Transition Services Agreement to provide transition support services, at FDB's cost and expense
- Under the Manufacturing Services Agreement, FDB will provide Atara with access to the flexible capacity and skilled team needed to manufacture clinical and commercial-stage therapies for its maturing and promising pipeline
- Atara is confident that this new partnership will not impact planned pre-approval Inspection for tab-cel MAA and future BLA submission
- Further focuses Atara's capital resources on development and commercialization of its pipeline
- The companies anticipate a closing date in April 2022 subject to customary closing conditions including HSR

**Upon closing, Atara's cash is expected to fund planned operations into Q4 2023, beyond the anticipated completion date of the ATA188 EMBOLD study<sup>1</sup>**



<sup>1</sup> Atara expects to report cash, cash equivalents and short-term investments of \$371.1 million as of December 31, 2021.

This information is preliminary, has not been audited, and is subject to change upon the audit of the company's financial statements for the year ended December 31, 2021

# Atara is the Most Advanced Allogeneic T Cell Therapy Company, at the Forefront of Process Science and Advanced Manufacturing Technology

---

## Our Success and Experience in Allogeneic T Cell Product Development is Well Established and Provides Significant Flexibility

- Proven capability to **manufacture at scale and store** new allogeneic T cell therapy product candidates designed in our lab
- Provides the ability to **periodically campaign our production** while maintaining appropriate levels of finished product inventory, that is readily available to deliver to patients in need within 3 days
- Enables us to work with a **full-scale manufacturing partner** who has the technical expertise and the appropriate capacity to **build the right amount of product supply** when needed for late-stage clinical trials and commercialization

## Strategic Partnership with Fujifilm Diosynth Biotechnologies (FDB) Delivers Several Advantages

- We retain and will continue to **invest in our research, product design, manufacturing and assay development**, for early stage and scale up phases
- Long-term agreement with FDB that gives us **access to expert cell therapy manufacturing** staff, and capacity for large-scale product runs when needed
- Atara will retain a **talented technical operations team** including process sciences, quality assurance and supply chain/logistics
- Over time, this partnership will allow us to **leverage our capital resources** on creating and developing additional innovative allogeneic cell therapies for patients in need